Calling All Neoantigen Experts Dedicated to the Clinical and Commercial Development of Next Generation Personalized Cancer Vaccines and Cellular Immunotherapies.
What Is the NeoAg Summit?
Returning to Boston for the 4th year, the NeoAg Summit is the only industry-focused meeting dedicated solely to the full end-to-end development and commercialization of neoantigen-based cancer immunotherapies.
Bringing together this exclusive community of over 300+ industry leaders from pharma, biotech, academia, regulatory bodies, solution and service providers, join your community to
- Advance neoantigen prediction to identify reliable targets
- Interrogate delivery platforms to maximize immunogenicity
- Reduce needle to needle time and scale manufacture
… to improve the commercial potential of personalized therapies.
How Will It Help You Deliver on the Promise of Personalized Cancer Vaccines and Cellular Immunotherapies?
Covering the full end-to-end landscape, this one meeting will equip your whole team with the insights and lessons learned from over 30+ expert speakers including; Genocea, Vaccibody, FDA, Achilles Therapeutics, to advance your prediction tools through to navigating regulatory requirements to reduce needle to needle time.
With case-study led presentations, interactive discussions, practical workshops and a scientific poster session, gain an in-depth breakdown of the clinical landscape and technology innovations to advance your pipeline to successfully treat patients in need.
Why Should You Attend?
If you are dedicated to weaponizing neoantigens to successfully target tumors, this is your one stop shop to gain the tools and connections you need to maximize the potential of your neoantigen therapeutic and advance your clinical pipeline.
Expert Speakers Include
What Can You Expect?
Hear What Our Attendees Say
"Great opportunity to learn how to develop and accelerate neoantigen related products not only from speakers but also participants and partners."
"The Neoantigen Summit is the focal point for updates in the cancer neoantigen vaccine field and should be attended by everybody with a keen interest in the field."
Proud To Partner With
Industry Development Partner: